Please select the option that best describes you:
What alternative adjuvant therapy do you recommend to an imatinib intolerant patient with high-risk GIST?
I have seen favorable clinical trial reports on dasatinib for metastatic disease, but no data on possible adjuvant use. NCCN guidelines suggest to consider sunitinib but do not cite any adjuvant data.
Answer from: Medical Oncologist at Academic Institution
This is an interesting questions, but one that requires more information. First, do you know what the mutation status of the patient is? Are they KIT exon 11, exon 9, pdgfr, or wildtype? This is helpful as your expected benefit from adjuvant imatinib varies based on this mutation (Joensuu, Jama Onco...
Sign in or Register to read more